RT Book, Section
A1 Damon, Lloyd E.
A1 Andreadis, Charalambos Babis
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1184166123
T1 Myelodysplastic Syndromes
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1184166123
RD 2023/09/26
AB Key  Clinical  Updates  in  Myelodysplastic  SyndromesA  novel  agent,  luspatercept,  has  been  developed  to  target  signaling  via  the  SMAD2–SMAD3  pathway  which  is  constitutively  increased  in  the  bone  marrow  cells  of  patients  with  MDS  and  ineffective  erythropoiesis.In  a  randomized  study,  luspatercept  induced  transfusion  independence  in  38%  of  lower-risk  MDS  patients  who  did  not  respond  to  growth  factor  therapy  compared  to  13%  in  the  placebo  arm.